These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32757307)

  • 1. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
    van der Wilk BJ; Eyck BM; Doukas M; Spaander MCW; Schoon EJ; Krishnadath KK; Oostenbrug LE; Lagarde SM; Wijnhoven BPL; Looijenga LHJ; Biermann K; van Lanschot JJB
    Br J Surg; 2020 Dec; 107(13):1791-1800. PubMed ID: 32757307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
    Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
    Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
    Eyck BM; Onstenk BD; Noordman BJ; Nieboer D; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Ann Surg; 2020 Feb; 271(2):245-256. PubMed ID: 31188203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.
    Vollenbrock SE; Voncken FEM; van Dieren JM; Lambregts DMJ; Maas M; Meijer GJ; Goense L; Mook S; Hartemink KJ; Snaebjornsson P; Ter Beek LC; Verheij M; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Br J Surg; 2019 Apr; 106(5):596-605. PubMed ID: 30802305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
    Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
    Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Chao YK; Chang Y; Yeh CJ; Chang HK; Tseng CK; Chuang WY
    Br J Surg; 2016 Dec; 103(13):1874-1879. PubMed ID: 27620361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Lee MH; Wen YW; Chang HK; Tseng CK; Liu YH
    Medicine (Baltimore); 2015 Feb; 94(8):e588. PubMed ID: 25715265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Wen YW; Chang HK; Tseng CK; Liu YH
    Eur J Surg Oncol; 2017 Dec; 43(12):2366-2373. PubMed ID: 29070435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of serial endoscopic ultrasound after chemoradiation in esophageal cancer.
    Bohle W; Kasper M; Zoller WG
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.
    Vollenbrock SE; van Dieren JM; Voncken FEM; van Turenhout ST; Kodach LL; Hartemink KJ; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Eur Radiol; 2020 May; 30(5):2425-2434. PubMed ID: 31965258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?
    Heneghan HM; Donohoe C; Elliot J; Ahmed Z; Malik V; Ravi N; Reynolds JV
    Ann Surg; 2016 Nov; 264(5):831-838. PubMed ID: 27741010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual carcinoma cells after chemoradiotherapy for esophageal squamous cell carcinoma patients: striving toward appropriate judgment of biopsy.
    Fujishima F; Taniyama Y; Nakamura Y; Okamoto H; Ozawa Y; Ito K; Ishida H; Konno-Kumagai T; Kasajima A; Taniuchi S; Watanabe M; Kamei T; Sasano H
    Dis Esophagus; 2018 Jul; 31(7):. PubMed ID: 29346536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of endoscopic esophageal findings for residual esophageal cancer after neoadjuvant chemoradiotherapy.
    van der Bogt RD; van der Wilk BJ; Nikkessen S; Krishnadath KK; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; Doukas M; van Lanschot JJB; Spaander MCW
    Endoscopy; 2021 Nov; 53(11):1098-1104. PubMed ID: 33652496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.
    Noordman BJ; Shapiro J; Spaander MC; Krishnadath KK; van Laarhoven HW; van Berge Henegouwen MI; Nieuwenhuijzen GA; van Hillegersberg R; Sosef MN; Steyerberg EW; Wijnhoven BP; van Lanschot JJ;
    JMIR Res Protoc; 2015 Jun; 4(2):e79. PubMed ID: 26121676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer.
    Giovannini M; Seitz JF; Thomas P; Hannoun-Levy JM; Perrier H; Resbeut M; Delpero JR; Fuentes P
    Endoscopy; 1997 Jan; 29(1):4-9. PubMed ID: 9083729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.